Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

800
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
800
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

927
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
927
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

711
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
711
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

649
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
649

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PHOMS: An apt and accurate acronym.

Archivos de la Sociedad Espanola de Oftalmologia·2024
Same author

Triazolopyrimidine herbicides are potent inhibitors of Aspergillus fumigatus acetohydroxyacid synthase and potential antifungal drug leads.

Scientific reports·2021
Same author

Calcium-dependent Nedd4-2 upregulation mediates degradation of the cardiac sodium channel Nav1.5: implications for heart failure.

Acta physiologica (Oxford, England)·2017
Same author

Child behaviour problems and childhood illness: development of the Eczema Behaviour Checklist.

Child: care, health and development·2016
Same author

A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.

Current oncology (Toronto, Ont.)·2015
Same author

Leishmaniasis involving the bone marrow of a patient with multiple myeloma.

Annals of hematology·2015

Related Experiment Video

Updated: Feb 13, 2026

Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

18.9K

Progressive multifocal leukoencephalopathy during ixazomib-based chemotherapy.

C P Sawicki1, S A Climans2, C C Hsia3

  • 1Division of Physical Medicine and Rehabilitation, Department of Medicine, The University of Toronto, Toronto, ON, Canada.

Current Oncology (Toronto, Ont.)
|March 7, 2018
PubMed
Summary
This summary is machine-generated.

Progressive multifocal leukoencephalopathy (PML) is a rare brain infection. This case report details a fatal PML occurrence in a multiple myeloma patient treated with ixazomib chemotherapy.

Keywords:
Progressive multifocal leukoencephalopathyixazomibmultiple myeloma

More Related Videos

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.6K

Related Experiment Videos

Last Updated: Feb 13, 2026

Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

18.9K
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.6K

Area of Science:

  • Neuroscience
  • Immunology
  • Oncology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, opportunistic central nervous system infection.
  • PML is caused by John Cunningham virus (JCV) reactivation, typically in immunocompromised individuals.
  • Multiple myeloma and its treatments are known risk factors for opportunistic infections.

Purpose of the Study:

  • To report the first documented case of PML in a patient treated with ixazomib-based chemotherapy for multiple myeloma.
  • To highlight the potential risk of PML in multiple myeloma patients undergoing novel therapeutic regimens.

Main Methods:

  • Case presentation of a 59-year-old male with multiple myeloma.
  • Diagnosis confirmed via MRI and JCV detection in cerebrospinal fluid.
  • Clinical course and treatment interventions (chemotherapy cessation, mirtazapine) were documented.

Main Results:

  • The patient developed severe neurological deficits consistent with PML.
  • Despite medical interventions, the patient experienced rapid neurological decline.
  • The patient died two months post-hospitalization.

Conclusions:

  • Ixazomib-based chemotherapy may be associated with an increased risk of PML in multiple myeloma patients.
  • Early recognition and diagnosis of PML are crucial, although treatment options remain limited.
  • This case underscores the importance of vigilance for opportunistic infections in immunocompromised cancer patients.